What is the share price of Sanofi India Ltd (SANOFI) today?
The share price of SANOFI as on 2nd April 2026 is ₹3265. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Sanofi India Ltd (SANOFI) share?
The past returns of Sanofi India Ltd (SANOFI) share are- Past 1 week: -2.05%
- Past 1 month: -16.28%
- Past 3 months: -21.17%
- Past 6 months: -30.67%
- Past 1 year: -44.43%
- Past 3 years: -43.07%
- Past 5 years: -59.18%
What are the peers or stocks similar to Sanofi India Ltd (SANOFI)?
The peers or stocks similar to Sanofi India Ltd (SANOFI) include:What is the dividend yield % of Sanofi India Ltd (SANOFI) share?
The current dividend yield of Sanofi India Ltd (SANOFI) is 3.81.What is the market cap of Sanofi India Ltd (SANOFI) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Sanofi India Ltd (SANOFI) is ₹7432.90 Cr as of 2nd April 2026.What is the 52 week high and low of Sanofi India Ltd (SANOFI) share?
The 52-week high of Sanofi India Ltd (SANOFI) is ₹6717 and the 52-week low is ₹3160.What is the PE and PB ratio of Sanofi India Ltd (SANOFI) stock?
The P/E (price-to-earnings) ratio of Sanofi India Ltd (SANOFI) is 22.75. The P/B (price-to-book) ratio is 8.64.Which sector does Sanofi India Ltd (SANOFI) belong to?
Sanofi India Ltd (SANOFI) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Sanofi India Ltd (SANOFI) shares?
You can directly buy Sanofi India Ltd (SANOFI) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Sanofi India Ltd
SANOFI Share Price
NSE₹3,265.000.08% (+2.60)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
SANOFI Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
SANOFI Performance & Key Metrics
SANOFI Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 22.75 | 8.64 | 3.81% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 34.78 | 5.49 | 0.61% |
100%
Analysts have suggested that investors can buy this stock
from 2 analysts
Price Upside
Earnings Growth
Rev. Growth
SANOFI Company Profile
Sanofi India Limited is engaged in the manufacture and sale of pharmaceutical products.
SUNPHARMA
PE Ratio
38.60
38.60
1Y Return
1.17%
1.17%
Buy Reco %
94.12
94.12
TORNTPHARM
PE Ratio
74.62
74.62
1Y Return
24.32%
24.32%
Buy Reco %
78.57
78.57
LUPIN
PE Ratio
31.99
31.99
1Y Return
13.18%
13.18%
Buy Reco %
72.22
72.22
DRREDDY
PE Ratio
18.45
18.45
1Y Return
5.85%
5.85%
Buy Reco %
51.61
51.61
CIPLA
PE Ratio
18.72
18.72
1Y Return
17.90%
17.90%
Buy Reco %
51.61
51.61
SANOFI Sentiment Analysis
SANOFI Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
SANOFI Stock Summary · March 2026
Sanofi India is undergoing a significant transformation, focusing on becoming an R&D-driven, AI-enabled biopharma organization while maintaining its leadership in the diabetes market. Despite facing flat domestic sales and a 2% decline in partnership sales due to inventory challenges, the company achieved a modest 1% increase in profit before tax, driven by effective cost management and operational efficiencies. The diabetes segment continues to show robust growth, supported by strategic partnerships and digital initiatives aimed at enhancing patient adherence. While EBITDA margins have reached an eight-quarter low, management remains optimistic about future performance, emphasizing the importance of stabilizing partnerships and maximizing existing therapeutic areas. The commitment to corporate social responsibility further strengthens its brand presence, aligning with long-term growth strategies.
SANOFI Stock Growth Drivers
SANOFI Stock Growth Drivers
7Business Transformation and Operational Efficiency
The company has undergone a significant transformation, modernizing its business model to become an R&D-driven,
Strong Performance in Diabetes Segment
Sanofi India has reported strong performance in the diabetes segment, maintaining market leadership in the
SANOFI Stock Challenges
SANOFI Stock Challenges
6Decline in Partnership Sales
The partnership segment has experienced a significant decline, with a reported 2% decrease year-over-year and
Flat Domestic Sales and Declining Export Performance
Domestic sales for 2025 were reported as flat, and there was a significant drop in
SANOFI Forecast
SANOFI Forecasts
Price
Revenue
Earnings
SANOFI Share Price Forecast
SANOFI Share Price Forecast
2026
Current
₹3,265.00
Baseline
Forecast for Apr 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
2026
Current
₹3,265.00
Baseline
Forecast for Apr 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
SANOFI Company Revenue Forecast
SANOFI Company Revenue Forecast
2025
Current
₹1.86
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
2025
Current
₹1.86
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
SANOFI Stock EPS (Earnings Per Share) Forecast
SANOFI Stock EPS (Earnings Per Share) Forecast
2025
Current
₹141.85
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹141.85
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
SANOFI
SANOFI
Income
Balance Sheet
Cash Flow
Quarterly Normal View
SANOFI Income Statement
SANOFI Income Statement
Quarterly Normal View
| Quarter | sep 2023 | dec 2023 | mar 2024 | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 572.90 | 546.60 | 578.90 | 503.50 | 526.30 | 528.80 | 539.20 | 415.00 | 480.30 | 422.60 | ||||||||||
Operating & Other expenses | 377.20 | 369.60 | 400.40 | 366.80 | 404.30 | 396.60 | 364.00 | 311.40 | 368.50 | 329.50 | ||||||||||
EBITDA | 195.70 | 177.00 | 178.50 | 136.70 | 122.00 | 132.20 | 175.20 | 103.60 | 111.80 | 93.10 | ||||||||||
| Depreciation/Amortization | 9.20 | 9.30 | 9.10 | 9.00 | 9.00 | 9.60 | 9.60 | 9.10 | 9.10 | 9.50 | ||||||||||
| PBIT | 186.50 | 167.70 | 169.40 | 127.70 | 113.00 | 122.60 | 165.60 | 94.50 | 102.70 | 83.60 | ||||||||||
| Interest & Other Items | 0.30 | 0.40 | 0.30 | 0.40 | 0.40 | 0.40 | 0.30 | 0.40 | 0.40 | 0.60 | ||||||||||
| PBT | 186.20 | 167.30 | 169.10 | 127.30 | 112.60 | 122.20 | 165.30 | 94.10 | 102.30 | 83.00 | ||||||||||
| Taxes & Other Items | 34.00 | 29.60 | 32.50 | 23.90 | 30.40 | 30.90 | 45.80 | 24.60 | 26.30 | 21.30 | ||||||||||
| Net Income | 152.20 | 137.70 | 136.60 | 103.40 | 82.20 | 91.30 | 119.50 | 69.50 | 76.00 | 61.70 | ||||||||||
| EPS | 66.08 | 59.89 | 59.31 | 44.90 | 35.69 | 39.64 | 51.89 | 30.18 | 32.99 | 26.79 |
SANOFI Company Updates
FY 2026FY 2026
Investor Presentation
Feb 26PDF
Oct 29PDF
SANOFI Stock Peers
SANOFI Past Performance & Peer Comparison
SANOFI Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Sanofi India Ltd | 22.75 | 8.64 | 3.81% |
| Sun Pharmaceutical Industries Ltd | 38.60 | 5.82 | 0.91% |
| Torrent Pharmaceuticals Ltd | 74.62 | 18.79 | 0.76% |
| Lupin Ltd | 31.99 | 6.07 | 0.52% |
SANOFI Stock Price Comparison
Compare SANOFI with any stock or ETFCompare SANOFI with any stock or ETF
SANOFI
SANOFI Holdings
SANOFI Shareholdings
SANOFI Promoter Holdings Trend
SANOFI Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
SANOFI Institutional Holdings Trend
SANOFI Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
SANOFI Shareholding Pattern
SANOFI Shareholding Pattern
SANOFI Shareholding History
SANOFI Shareholding History
Foreign Institutions
Mutual Funds Invested in SANOFI
Mutual Funds Invested in SANOFI
No mutual funds holding trends are available
Top 5 Mutual Funds holding Sanofi India Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 1.3420% | Percentage of the fund’s portfolio invested in the stock 0.20% | Change in the portfolio weight of the stock over the last 3 months -0.02% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 81/106 (-7) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.3356% | Percentage of the fund’s portfolio invested in the stock 0.33% | Change in the portfolio weight of the stock over the last 3 months -0.02% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 42/102 (-2) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.2284% | Percentage of the fund’s portfolio invested in the stock 1.10% | Change in the portfolio weight of the stock over the last 3 months -0.10% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 28/39 (0) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing SANOFI stock
smallcases containing SANOFI stock
Looks like this stock is not in any smallcase yet.
SANOFI Events
SANOFI Events
SANOFI Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
SANOFI Dividend Trend
No dividend trend available
SANOFI Upcoming Dividends
SANOFI Upcoming Dividends
Cash Dividend
Ex DateEx DateApr 22, 2026
Final
Final | Div/Share: ₹48.00
Dividend/Share
₹48.00
Ex DateEx Date
Apr 22, 2026
SANOFI Past Dividends
SANOFI Past Dividends
Cash Dividend
Ex DateEx DateNov 7, 2025
Interim
Interim | Div/Share: ₹75.00
Dividend/Share
₹75.00
Ex DateEx Date
Nov 7, 2025
Cash Dividend
Ex DateEx DateApr 25, 2025
Final
Final | Div/Share: ₹117.00
Dividend/Share
₹117.00
Ex DateEx Date
Apr 25, 2025
Cash Dividend
Ex DateEx DateMay 3, 2024
Final
Final | Div/Share: ₹117.00
Dividend/Share
₹117.00
Ex DateEx Date
May 3, 2024
Cash Dividend
Ex DateEx DateMar 7, 2024
Interim
Interim | Div/Share: ₹50.00
Dividend/Share
₹50.00
Ex DateEx Date
Mar 7, 2024
Cash Dividend
Ex DateEx DateApr 28, 2023
Final
Final | Div/Share: ₹194.00
Dividend/Share
₹194.00
Ex DateEx Date
Apr 28, 2023
SANOFI Stock News & Opinions
SANOFI Stock News & Opinions
Articles & Videos
Corporate
Sanofi India to convene AGM
Sanofi India announced that the 70th Annual General Meeting(AGM) of the company will be held on 29 April 2026.Powered by Capital Market - Live
1 week agoCapital Market - Live
Corporate
Board of Sanofi India recommends final dividend
Sanofi India announced that the Board of Directors of the Company at its meeting held on 25 February 2026, inter alia, have recommended the final dividend of Rs 48 per equity Share (i.e. 480%) , subject to the approval of the shareholders.Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Sanofi India standalone net profit declines 32.42% in the December 2025 quarter
Net profit of Sanofi India declined 32.42% to Rs 61.70 crore in the quarter ended December 2025 as against Rs 91.30 crore during the previous quarter ended December 2024. Sales declined 18.47% to Rs 419.80 crore in the quarter ended December 2025 as against Rs 514.90 crore during the previous quarter ended December 2024. For the full year,net profit declined 20.99% to Rs 326.70 crore in the year ended December 2025 as against Rs 413.50 crore during the previous year ended December 2024. Sales declined 8.73% to Rs 1837.40 crore in the year ended December 2025 as against Rs 2013.20 crore during the previous year ended December 2024. ParticularsQuarter EndedYear EndedDec. 2025Dec. 2024% Var.Dec. 2025Dec. 2024% Var. Sales419.80514.90 -18 1837.402013.20 -9 OPM %21.5122.98 -26.7424.38 - PBDT92.50123.80 -25 509.30505.80 1 PBT83.00114.20 -27 472.00469.10 1 NP61.7091.30 -32 326.70413.50 -21 Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Sanofi India to hold board meeting
Sanofi India will hold a meeting of the Board of Directors of the Company on 25 February 2026.Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Sanofi India standalone net profit declines 7.54% in the September 2025 quarter
Net profit of Sanofi India declined 7.54% to Rs 76.00 crore in the quarter ended September 2025 as against Rs 82.20 crore during the previous quarter ended September 2024. Sales declined 9.27% to Rs 475.40 crore in the quarter ended September 2025 as against Rs 524.00 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales475.40524.00 -9 OPM %28.2322.84 - PBDT138.70121.60 14 PBT129.60112.60 15 NP76.0082.20 -8 Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Board of Sanofi India recommends Interim Dividend
Sanofi India announced that the Board of Directors of the Company at its meeting held on 29 October 2025, has recommended a Interim Dividend of Rs.75 per share (i.e.750%), subject to the approval of the shareholders.Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Board of Sanofi India approves change in directorate
The Board of Sanofi India at its meeting held on 27 October 2025 has approved the following- Appointment of Deepak Arora (DIN: 07495638) as an Additional Director of the Company with effect from 27 October 2025 and as a Managing Director (Key Managerial Personnel) of the Company for a term of 3 (three) years effective from 27 October 2025. Stepping down of Rachid Ayari as Interim Managing Director of the Company with effect from close of 26 October 2025. However, Rachid Ayari would continue to serve the Company in his role as Whole time Director and Chief Financial Officer of the Company.Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Sanofi India to table results
Sanofi India will hold a meeting of the Board of Directors of the Company on 29 October 2025.Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Sanofi India announces cessation of senior management personnel
Sanofi India announced that Surabhi Kaul, People Director - SEA&I, will cease to be a Senior Management Personnel (SMP) of the Company effective from the close of business on 14 August 2025, in view of her movement to another role within the Sanofi group. Powered by Capital Market - Live
7 months agoCapital Market - Live
Earnings
Sanofi India standalone net profit declines 32.79% in the June 2025 quarter
Net profit of Sanofi India declined 32.79% to Rs 69.50 crore in the quarter ended June 2025 as against Rs 103.40 crore during the previous quarter ended June 2024. Sales declined 12.34% to Rs 406.30 crore in the quarter ended June 2025 as against Rs 463.50 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales406.30463.50 -12 OPM %23.3624.96 - PBDT103.20120.10 -14 PBT94.10111.10 -15 NP69.50103.40 -33 Powered by Capital Market - Live
8 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of -9.1%, vs industry avg of 9.88%
Over the last 5 years, market share decreased from 1.18% to 0.44%
Over the last 5 years, net income has grown at a yearly rate of -7.31%, vs industry avg of 19.69%